Dr. Vinay Prasad Said He Would Deliver New COVID Vaccine RCTs. He Failed and Should STFU.
Pfizer and BioNTech announced they are halting a U.S. phase‑III trial of their updated COVID‑19 vaccine aimed at adults 50‑64 because enrollment fell far short of the planned 25,000‑30,000 participants. The companies said the decision was unrelated to safety or efficacy, citing recruitment difficulties as the primary obstacle. The pause comes after former FDA vaccine chief Dr. Vinay Prasad repeatedly called for new randomized trials but failed to mobilize support for enrollment. Industry observers see the setback as a warning that public fatigue and polarized attitudes are making large‑scale COVID‑19 studies increasingly hard to execute.
The Competitive Fiction of a “Best” Obesity Treatment
Novo Nordisk issued a press release claiming its Wegovy (semaglutide) tablets outperform the newly approved orforglipron (Foundayo) tablets, basing the claim on a simulated treatment comparison to be presented at the Obesity Medicine Association meeting. The article warns that such...
Signal Reprogramming as an Approach to the Challenge of cGAS-STING Overactivation
A new open‑access review highlights the cGAS‑STING pathway as a central driver of ovarian aging, linking DNA and mitochondrial leaks to chronic inflammation and follicle loss. The authors propose three therapeutic angles: small‑molecule inhibitors that silence cGAS or STING, upstream...
RFK Jr. Appointed a Saboteur to Run the CDC’s Vaccine Panel — And Didn’t Know It
Dr. Robert Malone, a co‑inventor of mRNA vaccine technology, quit the CDC’s Advisory Committee on Immunization Practices (ACIP) alleging internal sabotage. He claims that a person personally appointed by RFK Jr. to oversee ACIP operations acted as a mole, undermining Secretary...
Soquelitinib
Corvus Pharmaceuticals announced soquelitinib (CPI‑818), an oral covalent inhibitor that irreversibly engages ITK at Cys442 while sparing the related kinase RLK. The selectivity addresses the broader off‑target activity seen with earlier covalent ITK agents such as ibrutinib. Soquelitinib is currently...
Agenus Announces Data From Phase II Study of BOT+BAL in Combination with Agent-797 in PD-1 Refractory Gastroesophageal Cancer to Be...
Agenus announced that data from an investigator‑initiated Phase II trial of its multi‑mechanistic immunotherapy combo—botensilimab (BOT), balstilimab (BAL) and the allogeneic iNKT cell therapy agenT‑797—will be presented at the AACR Annual Meeting in April 2026. The study targets patients with PD‑1‑refractory gastroesophageal...
100% Pharma Tariffs, Lilly's Oral GLP-1 Approval, and a $12B Week in Biotech M&A – This Week in Biotech #94
The White House announced 100% tariffs on branded drug imports from countries lacking trade agreements, prompting biotech firms to reassess supply‑chain and pricing strategies. Eli Lilly secured a rapid FDA approval for Foundayo, the first oral small‑molecule GLP‑1 for chronic weight...
Proposing Atrial Fibrillation and Heart Failure to Be Manifestations of the Same Condition
Researchers propose that atrial fibrillation and heart failure share a common molecular origin: reduced expression of the transcription factor TBX5. Mouse models lacking TBX5 in the atria develop arrhythmias and gene‑expression patterns that closely resemble heart‑failure signatures. Human atrial tissue...
Oral Microbiome Changes in the Correlation Between Periodontal Disease and Cognitive Decline
Researchers analyzed data from 1,157 participants in the Taizhou Imaging Study, linking periodontal health, salivary microbiome composition, and cognitive function. They found five clinical periodontal indices inversely related to cognition and identified ten bacterial genera, 21 functional pathways, and two...
Researchers Develop Nasally Delivered DNA Vaccine for Tuberculosis
Johns Hopkins researchers have created an intranasal DNA vaccine that fuses the relMtb and Mip3α genes to target drug‑tolerant tuberculosis persisters. In mouse models the vaccine accelerated bacterial clearance, lowered lung inflammation and prevented relapse when combined with standard therapy....
Innate Pharma to Participate in the Kempen Life Sciences Conference
Innate Pharma announced that senior executives will hold one‑on‑one investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 15‑16, 2026. The biotech firm will use the event to showcase its pipeline, including the Nectin‑4 ADC IPH4502, the...
PTSD Is Almost Incurable. Psychedelics Can Help — but only in Three U.S. States and Australia
Australia has opened a regulated pathway for MDMA‑assisted psychotherapy to treat post‑traumatic stress disorder, making it one of the few countries where the drug can be used medically. Early data from Dr. Ranil Gunewardene’s practice show more than 50 % of...
Anthropic Buys Stealth Dimension-Backed Coefficient Bio in $400M+ Stock Deal
Anthropic has acquired stealth biotech startup Coefficient Bio in a stock transaction valued at just over $400 million. Coefficient Bio, founded eight months ago, develops AI models aimed at accelerating biological research and pursuing artificial superintelligence for science. The deal brings...
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. Difficile Infection Will Continue...
Vedanta Biosciences announced that the independent Data Monitoring Committee has completed the first prespecified interim analysis of its Phase 3 RESTORATiVE303 trial and recommended the study continue unchanged. The interim data showed efficacy surpassing the futility threshold with no new safety...
SV Health Investors Acquires EpiVax
SV Health Investors (SVHI) announced the acquisition of EpiVax, a Providence‑based bioanalytical CRO that specializes in immunogenicity risk assessments for pharma and biotech firms. The deal adds a proven scientific platform, including the ISPRI predictive software and cell‑based assays, to...
Boston University to Apply Machine Learning to Alzheimer’s Biomarker and Cognitive Data
Boston University, leading the AI for Alzheimer’s Disease (AI4AD) consortium, is coordinating 11 research institutes to apply machine learning to massive genomic, biomarker and cognitive datasets. The team is building the PreSiBO database, which tags predictor, signature, biomarker and outcome...
Pharmaceutical Giant Pfizer Forced To Shut Down Updated COVID Vaccine Trials
Pfizer announced it is halting development of its updated COVID‑19 vaccine candidates, ending ongoing Phase 2/3 trials that targeted newer variants. The decision follows mixed efficacy data and waning commercial demand as the pandemic recedes. Pfizer will redirect resources toward...
TRPM3: The Ion Channel Behind Pain, Migraines, and ME/CFS
TRPM3 is a calcium‑permeable ion channel activated by heat and neurosteroids such as pregnenolone sulfate, playing a central role in pain perception, insulin secretion, and vascular regulation. Genetic variants in the TRPM3 gene have been associated with heightened susceptibility to...
Pfizer Halts COVID Shot Trial Because They Can’t Find Enough Test Subjects Willing to Take Another Booster Shot
Pfizer and BioNTech have halted a large U.S. clinical trial of an updated COVID‑19 booster after failing to enroll enough healthy adults aged 50‑64. The study required tens of thousands of participants, but recruitment stalled amid a sharp decline in...
Asundexian
Bayer’s oral factor XIa inhibitor asundexian (BAY 2433334) has delivered positive Phase 3 data in the OCEANIC‑STROKE trial, positioning it as a potential first‑in‑class therapy for secondary stroke prevention. The drug aims to block pathological clot formation while minimizing the bleeding complications common...
Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava
Shionogi completed a $2.5 billion acquisition of global rights to Radicava from Tanabe Pharma, adding an approved ALS treatment to its portfolio. The deal transfers all intellectual property, sales rights and the existing commercial team, delivering an estimated $700 million in annual...
NR0B2 Is Protective of Cartilage, But Expression Decreases as Osteoarthritis Progresses
Researchers identified the orphan nuclear receptor NR0B2 (also known as SHP) as a protective factor in cartilage, with its expression markedly reduced in osteoarthritic tissue. In male mice, global or chondrocyte‑specific deletion of Nr0b2 worsened pain and joint damage after...
Pharma Pulse: Foundayo’s FDA Approval and the Strategic Risk of Pharmacy Data Consolidation
Eli Lilly’s Foundayo became the first new molecular entity approved under the FDA’s National Priority Voucher pilot, clearing in a record 50 days. It is the only GLP‑1 weight‑loss pill that can be taken without food or water restrictions, aiming to...
What Will Approval of Foundayo GLP-1 Tablets Bring?
The FDA has approved Foundayo (orforglipron), the first non‑peptide oral GLP‑1 tablet for obesity. As a small‑molecule drug, it sidesteps the manufacturing complexities that plagued peptide injectables like semaglutide and tirzepatide. Daily oral dosing promises easier adherence compared with weekly...
What Didn’t Exist Three Years Ago
The American Association for Cancer Research (AACR) annual meeting highlighted the latest direction of early‑stage drug development. This year’s sessions featured two prostate‑cancer candidates using mechanisms that were not in the clinic just eighteen months ago. The preview spotlights a...
Novel Therapeutic and Trial Approaches for Lysosomal Storage Disorders with Polaryx’s Alex Yang — Episode 249
In episode 249 of the Xtalks Life Science Podcast, Alex Yang, JD, LLM, CEO of Polaryx, discusses the company’s mission to develop disease‑modifying small‑molecule therapies for rare pediatric lysosomal storage disorders. Yang leverages more than 25 years of experience across...
Loargys (Pegzilarginase) Wins FDA Nod for Ultrarare Metabolic Disorder After Earlier Setbacks
The U.S. FDA granted accelerated approval to Loargys (pegzilarginase‑nbln) for treating arginase‑1 deficiency (ARG1‑D), an ultrarare metabolic disorder affecting roughly 250 Americans. Loargys, a recombinant human arginase‑1 enzyme, is the first therapy shown to lower plasma arginine levels, achieving about...
Nanotechnology Sensor Reads Creatinine in Seconds for Rapid Kidney Testing
Researchers at Tohoku University and City College of New York unveiled a nanotechnology‑based creatinine biosensor that reads concentrations from 1 to 300 mg/dL in about 35 seconds. The device uses a platinum‑nanoparticle polymer composite tuned near the percolation threshold, eliminating the...
Pharmaceutical Executive Daily: Trump Administration Delays Appeal of Federal Ruling Blocking Vaccine Policy Overhaul
The Trump administration has postponed filing an appeal against a federal judge’s injunction on RFK Jr.’s vaccine policy overhaul, citing internal debates over election‑year politics. Meanwhile, Biogen announced a $5.6 billion cash acquisition of Apellis Pharmaceuticals, paying $41 per share—a premium of...
Being Specific About Being General: Vaccines Edition
Emerging platforms are converging on a universal influenza vaccine, aiming to replace strain‑specific shots that require yearly reformulation. Companies such as Versatope are leveraging engineered bacterial outer‑membrane vesicles to deliver precise antigens, while NIH’s FluMos‑v2 expands hemagglutinin coverage to six...
A Deep Dive Into INN Proposed List 134
The World Health Organization released its International Nonproprietary Names (INN) Proposed List 134, introducing 124 new drug names slated for future approval. The list features a notable influx of antiviral and oncology agents, as well as the first biosimilar designations...
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of...
Vertex Pharmaceuticals announced that the U.S. FDA has approved label expansions for its CFTR modulators ALYFTREK and TRIKAFTA. ALYFTREK is now indicated for patients six years and older whose CFTR gene produces any functional protein, while TRIKAFTA’s indication now includes...
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with...
Zai Lab and Amgen have entered a global collaboration to test Zai Lab’s DLL3‑targeting antibody‑drug conjugate, zocilurtatug pelitecan (zoci), together with Amgen’s FDA‑approved bispecific T‑cell engager IMDELLTRA® in extensive‑stage small cell lung cancer (ES‑SCLC). Amgen will sponsor and lead a...
The New Infrastructure of Drug Commercialization
The pharmaceutical commercialization landscape is undergoing a rapid overhaul, driven by heightened government pricing controls, the rise of complex biologics, cell and gene therapies, and advanced data systems. Cold‑chain logistics have become a strategic priority as temperature‑sensitive products proliferate, while...
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
Cyclerion Therapeutics and privately‑held Korsana Biosciences have signed an all‑stock merger agreement, creating a combined company that will operate as Korsana Biosciences and trade on Nasdaq under the ticker KRSA. Korsana secured an oversubscribed $380 million private placement that will fund...
Amprion Grows Global Footprint with Australian Partnership & Expanded Research Collaborations
Amprion announced a strategic partnership with Macquarie University to launch Australia’s first clinical alpha‑synuclein seed amplification testing site, expanding its global footprint. The company will continue collaborative research with the Michael J. Fox Foundation in 2026, integrating its SAAmplify‑ɑSYN assay into...
Smart Drugs Are Here
A recent proof‑of‑concept study introduces DNA‑drug conjugates (DDCs) that turn “smart drugs” into programmable therapies. DDCs use split DNA strands as logic gates to release payloads only when specific biomarker combinations are present, offering higher specificity than antibody‑drug conjugates (ADCs)....
The Biotech Bi-Weekly: Cell Barcoding, Compound Optimization and the Trillion Cell Atlas
The biotech sector is witnessing a wave of collaborations and product launches aimed at accelerating drug discovery and expanding genomic knowledge. Biotium introduced the ViaPlex™ 2‑Color Cell Barcoding Kit, enabling multiplex analysis of up to 15 cell populations in a...
Smart IUD Could ‘Provide Insights We’ve Never Had Before’
Verso Biosense, based in Oxfordshire, is creating a wireless smart IUD that continuously records uterine temperature and oxygen levels. The device aims to generate real‑time data to help clinicians understand why some IVF cycles fail and to identify conditions that...
Remaining Challenges in the Development of Partial Reprogramming Therapies
Partial reprogramming—brief exposure to Yamanaka factors OCT4, SOX2, KLF4 and MYC—has demonstrated modest rejuvenation in mouse studies but carries a substantial cancer risk if cells slip into full pluripotency. Funding is concentrated in a few well‑capitalized firms, notably Altos Labs,...
Productivity Enhancing Bioreactor for Scalable Organoid Culture
AMSBIO introduced RPMotion, a spinning organoid bioreactor that accelerates and automates 3‑D cell culture for drug discovery, disease modeling and regenerative medicine. The system delivers up to five‑fold faster organoid expansion while cutting reagent costs by roughly 60% and labor...
Boston Scientific Receives FDA Clearance for the Asurys Fluid Management System
Boston Scientific announced FDA 510(k) clearance for its Asurys Fluid Management System, a device that provides automated irrigation and intrarenal pressure control during endoscopic urologic procedures such as ureteroscopy. The system integrates with the LithoVue Elite single‑use digital ureteroscope, allowing...
Regulating Payment of Participant Data in Clinical Trials
A team of scholars led by Steve Calandrillo proposes that FDA and IRBs adopt fair‑market‑value (FMV) payments for the data participants generate in clinical trials. Currently, participants receive modest compensation—about $4,000 per year—solely for trial involvement, not for the valuable...
BREAKING STUDY: Half of COVID-19 Vaccinated Military Personnel Suffered Subclinical Heart Stress
A new longitudinal study of 83 healthy military personnel tracked cardiac biomarkers after two mRNA COVID‑19 vaccine doses. Within two weeks of the second shot, 49% of participants exhibited a rise in NT‑proBNP exceeding 1.5 times their baseline, indicating subclinical...
AZD5004
Elecoglipron (ECC5004/AZD5004), an oral small‑molecule GLP‑1 receptor agonist, completed Phase 2 trials in type 2 diabetes and obesity, meeting primary endpoints in the SOLSTICE and VISTA studies. AstraZeneca licensed global rights from Eccogene for an upfront payment of $185 million and potential milestones...
CellCentric Initiates DOMMINO-1, a Pivotal Phase 2 Clinical Trial of Inobrodib in Combination with Pomalidomide and Dexamethasone (InoPd) in Relapsed...
CellCentric has launched the pivotal Phase 2 DOMMINO‑1 trial of inobrodib 20 mg combined with pomalidomide and dexamethasone (InoPd) in heavily pretreated relapsed or refractory multiple myeloma (RRMM) patients. The first dose was administered at The Royal Marsden in London, with additional...
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion...
ImmunityBio secured $75 million of non‑dilutive financing under its existing royalty‑interest purchase agreement with Oberland Capital, raising total committed capital to $375 million. At the same time, Nant Capital converted $25 million of debt into common stock, reducing the company’s liabilities. The combined...
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium Abscessus Complex Lung Disease
AN2 Therapeutics has begun a Phase 2 investigator‑initiated trial of epetraborole, an oral leucyl‑tRNA synthetase inhibitor, for pulmonary disease caused by Mycobacterium abscessus. The randomized, double‑blind study will enroll 84 patients across roughly 10‑15 U.S. sites and is led by Dr. Kevin...
Is AI Ready to Transform COA Development?
Artificial intelligence is reshaping clinical development by augmenting, not replacing, human expertise. AI already accelerates medical imaging, compound discovery and COVID‑19 vaccine modeling, compressing timelines from years to months. In clinical outcome assessment (COA) translation, AI can support draft translation...
SignateraTM MRD Identifies Breast Cancer Patients Who Can Forgo Surgery
Natera’s Signatera circulating‑tumor DNA test was shown in a prospective Clinical Cancer Research study to identify older women (≥70) with early‑stage ER⁺/HER2‑ breast cancer who can safely forgo surgery and remain progression‑free on primary endocrine therapy. Baseline MRD‑negative patients (68%...
